Sugi Predict

Sugi Predict / Compounds / SCHEMBL29801693

SCHEMBL29801693

SCHEMBL29801693

COc1cccc(NC2=NC(=O)/C(=C/c3c[nH]c4ccccc34)S2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRKCB P05771 1/20 0.50
▸ MAPK14 Q16539 1/20 0.43
▸ MEN1 O00255 6/20 0.42
▸ KMT2A Q03164 6/20 0.42
▸ MAPT P10636 3/20 0.42
▸ SENP8 Q96LD8 2/20 0.41
▸ SENP7 Q9BQF6 2/20 0.41
▸ SENP6 Q9GZR1 2/20 0.41
▸ CASP3 P42574 1/20 0.41
▸ EPAS1 Q99814 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ NTRK1 P04629 2/20 0.40
▸ FLT3 P36888 2/20 0.40
▸ ALOX5 P09917 2/20 0.40
▸ PRKD3 O94806 1/20 0.40
▸ ABL1 P00519 1/20 0.40
▸ RET P07949 1/20 0.40
▸ PDGFRB P09619 1/20 0.40
▸ LTK P29376 1/20 0.40
▸ KDR P35968 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23361926 1.00 PRKCB (0.50) PRKCBMAPK14MEN1KMT2AMAPT
SCHEMBL23361927 1.00 PRKCB (0.50) PRKCBMAPK14MEN1KMT2AMAPT
SCHEMBL21074342 0.88 SENP8 (0.52) PRKCBMEN1KMT2AMAPTSENP8
SCHEMBL29801391 0.88 SENP8 (0.52) PRKCBMEN1KMT2AMAPTSENP8
SCHEMBL29801683 0.85 SENP7 (0.44) PRKCBMEN1KMT2AMAPTSENP8
SCHEMBL19859149 0.85 SENP7 (0.44) PRKCBMEN1KMT2AMAPTSENP8
SCHEMBL21048266 0.85 MIF (0.42) PRKCBMAPK14MEN1KMT2AMAPT
SCHEMBL21048265 0.85 MIF (0.42) PRKCBMAPK14MEN1KMT2AMAPT
SCHEMBL21074378 0.85 STING1 (0.43) PRKCBMAPK14MEN1KMT2AMAPT
SCHEMBL29801540 0.85 PRKCB (0.47) PRKCBMEN1KMT2AMAPTSENP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114929217-A Pharmaceutical composition for treating multiple sclerosis based on AMPK inhibitory function and zinc homeostasis control function 锌医疗公司 2022-08-19 — — CN claimed
US-12343335-B2 Pharmaceutical composition for treating multiple sclerosis on basis of AMPK inhibitory function and zinc homeostasis control function ZINCURE CORP. (KR) 2025-07-01 — — US disclosed
US-20230000839-A1 PHARMACEUTICAL COMPOSITION FOR TREATING MULTIPLE SCLEROSIS ON BASIS OF AMPK INHIBITORY FUNCTION AND ZINC HOMEOSTASIS CONTROL FUNCTION ZINCURE CORP. (KR) 2023-01-05 — — US disclosed
CN-114929217-A Pharmaceutical composition for treating multiple sclerosis based on AMPK inhibitory function and zinc homeostasis control function 锌医疗公司 2022-08-19 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230000839-A1 PHARMACEUTICAL COMPOSITION FOR TREATING MULTIPLE SCLEROSIS ON BASIS OF AMPK INHIBITORY FUNCTION AND ZINC HOMEOSTASIS CONTROL FUNCTION PRKAB1, PRKAB2, PRKAG1 PRKCB 7/4885MAPK14 1866/4885MEN1 3953/4885
US-12343335-B2 Pharmaceutical composition for treating multiple sclerosis on basis of AMPK inhibitory function and zinc homeostasis control function PRKAB1, PRKAB2, PRKAG1 PRKCB 7/4885MAPK14 1866/4885MEN1 3953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.